Investigational Drug Information for SGN-CD19A
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug SGN-CD19A?
SGN-CD19A is an investigational drug.
There have been 80 clinical trials for SGN-CD19A.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 30th 2022.
The most common disease conditions in clinical trials are Lymphoma, Lymphoma, Non-Hodgkin, and Hodgkin Disease. The leading clinical trial sponsors are Seagen Inc., Seattle Genetics, Inc., and Millennium Pharmaceuticals, Inc.
There are one hundred and fifty-four US patents protecting this investigational drug and two international patents.
Summary for SGN-CD19A
| US Patents | 154 |
| International Patents | 2,515 |
| US Patent Applications | 633 |
| WIPO Patent Applications | 496 |
| Japanese Patent Applications | 166 |
| Clinical Trial Progress | Phase 3 (2022-09-30) |
| Vendors | 1 |
Recent Clinical Trials for SGN-CD19A
| Title | Sponsor | Phase |
|---|---|---|
| A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors | Seagen Inc. | Phase 1 |
| A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma | Takeda | Phase 4 |
| A Study of SGN-ALPV in Advanced Solid Tumors | Seagen Inc. | Phase 1 |
Clinical Trial Summary for SGN-CD19A
Top disease conditions for SGN-CD19A
Top clinical trial sponsors for SGN-CD19A
US Patents for SGN-CD19A
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| SGN-CD19A | See Plans and Pricing | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | Fundacio Institut de Recerca Biomedica (IRB Barcelona) (Barcelona, ES) Institucio Catalana de Recerca I Estudis Avancats (Barcelona, ES) | See Plans and Pricing |
| SGN-CD19A | See Plans and Pricing | Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) | BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) | See Plans and Pricing |
| SGN-CD19A | See Plans and Pricing | Peptidomimetic macrocycles as modulators of MCL-1 | AILERON THERAPEUTICS, INC. (Cambridge, MA) | See Plans and Pricing |
| SGN-CD19A | See Plans and Pricing | Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors | AbbVie Inc. (North Chicago, IL) | See Plans and Pricing |
| SGN-CD19A | See Plans and Pricing | Compositions comprising bacterial strains | 4D Pharma Research Limited (GB) | See Plans and Pricing |
| SGN-CD19A | See Plans and Pricing | Compositions comprising bacterial strains | 4D Pharma Research Limited (Aberdeen, GB) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for SGN-CD19A
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| SGN-CD19A | Australia | AU2013273242 | 2032-06-06 | See Plans and Pricing |
| SGN-CD19A | Australia | AU2019204269 | 2032-06-06 | See Plans and Pricing |
| SGN-CD19A | Canada | CA2875918 | 2032-06-06 | See Plans and Pricing |
| SGN-CD19A | China | CN104603288 | 2032-06-06 | See Plans and Pricing |
| SGN-CD19A | Denmark | DK2859120 | 2032-06-06 | See Plans and Pricing |
| SGN-CD19A | European Patent Office | EP2859120 | 2032-06-06 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
